Bristol-Myers Squibb will present data from 14 abstracts pertaining to its rheumatoid arthritis therapy Orencia (abatacept) at the European League Against Rheumatism (EULAR) 2015 Annual Meeting.
Rheumatoid arthritis is a systemic, chronic autoimmune disease marked by inflammation in the joints, which causes joint damage, chronic pain, swelling and stiffness. The disease leads to a limited range of motion and decreased function of the joints. The condition is more frequent in women (75 percent) than in men.
Orencia is a therapy used to decrease signs and symptoms of the disease by inhibiting the progression of structural damage and improving physical function in adult patients with moderate to severe forms of active rheumatoid arthritis.
The presentations will include safety analyses of efficacy of Orencia in anti-citrullinated, protein antibodies-positive (ACPA+), highly-active early moderate to severe types of rheumatoid arthritis in individuals who enrolled the Phase 3 AVERT study. Exploratory data from the 2-year Phase 3 AMPLE trial, which assessed Orencia versus adalimumab in ACPA+ moderate to severe rheumatoid arthritis patients, will also be presented. 9 more abstracts and their results will be published in EULAR’s program book.
“Biologic markers, like ACPA, are key to helping rheumatologists diagnose RA patients earlier in the disease process. As a leader in immunoscience, Bristol-Myers Squibb is proud to present new results at EULAR that will provide further data on the activity of Orencia in this patient population,” said Douglas Manion, who is the Head of Specialty Development, Bristol-Myers Squibb.
Bristol-Myers Squibb presentations can be reviewed here.
More Companies At EULAR
Roche has been invited to participate in the European League Against Rheumatism Annual Congress (EULAR 2015). The company will present data from the RoACTEMRA and MabThera trials for the treatment of rheumatoid arthritis, and has already announced in a press release ahead of the presentation that the novel therapies may offer significant improvements for patients suffering from these conditions. According to Roche, the data will reveal the company’s commitment to the treatment of autoimmune diseases, as well as the depth and breadth of the medical options they are currently developing. The company will present new results from RoACTEMRA in patients with early rheumatoid arthritis and systemic sclerosis (SSc), which is a life-threatening condition with severe lack of therapeutic options, as well as its studies on systemic juvenile idiopathic arthritis (sJIA), which is a serious type of pediatric arthritis children, and on other rare diseases characterized by inflammation of blood vessels.
